Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 6/26/2017 3:02:29 PM - Followers: 382 - Board type: Free - Posts Today: 16


Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.        

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Statement of Changes in Beneficial Ownership (4) 06/14/2017 08:07:08 AM
MNKD News: Current Report Filing (8-k) 06/01/2017 04:32:50 PM
MNKD News: MannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil 05/31/2017 06:00:00 PM
MNKD News: MannKind Provides Update on Senior Management 05/30/2017 09:00:00 AM
MNKD News: Current Report Filing (8-k) 05/23/2017 05:25:24 PM
#24271  Sticky Note 1 Still AFREZZA uses up to 400% more TREND1 06/23/17 11:44:05 AM
#23743  Sticky Note $MNKD MannKind and Biomm Enter Into Distribution Agreement $Pistol Pete$ 06/01/17 01:49:35 AM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#24324   Good answer. TREND1 06/26/17 03:02:29 PM
#24323   From your mouth to Gods ears! tyfoidhana 06/26/17 02:58:23 PM
#24322   Keep the faith, Scripts are going higher this Friday. TREND1 06/26/17 01:51:17 PM
#24321   What we need is scripts this Friday to tyfoidhana 06/26/17 01:35:01 PM
#24320   Bid support is strong but not enough ask no shorts 06/26/17 12:14:03 PM
#24319   GO MNKD RSI 5 > 70 TREND1 06/26/17 11:54:32 AM
#24318   Be careful about believing stories and fairy tales martind18 06/26/17 11:53:04 AM
#24317   Sting McCoy TREND1 06/26/17 10:34:52 AM
#24316 WHS 06/26/17 10:14:50 AM
#24315   Go MNKD RSI 5 > 70 TREND1 06/26/17 09:36:15 AM
#24313   Big week. Should be telling imo no shorts 06/26/17 09:05:28 AM
#24312   I am beginning to see why you are TREND1 06/26/17 09:04:03 AM
#24311   Why are you comparing monthly with quarterly data TREND1 06/26/17 05:52:45 AM
#24310   Trend or no Trend, this stock is driven tx_farmer 06/26/17 12:31:33 AM
#24309   Sometimes it's hard to follow the trend ?? Phaeton 06/26/17 12:05:49 AM
#24308   MNKD could do $3 Million in sales this Aloha96707 06/25/17 11:34:35 PM
#24307 WHS 06/25/17 09:01:06 PM
#24306   No wonder they cannot get the refill numbers Son o War 06/25/17 05:39:07 PM
#24305   Did MNKD solve that 7.4 million problem ? TREND1 06/25/17 02:06:42 PM
#24304   The trend will definitely be positive. All of Phaeton 06/25/17 01:39:56 PM
#24303   Russell 3000 balancing caused the afternoon sell off. Hypi 06/25/17 01:04:32 PM
#24302   See my up date every Friday TREND1 06/25/17 12:04:29 PM
#24301   Posted this board every Friday for free TREND1 06/25/17 12:02:49 PM
#24300   Where can I find the most updated script numbers? Son o War 06/25/17 11:10:59 AM
#24298   What are you talking about when you say,"Hell nobodysbusiness 06/24/17 09:01:04 PM
#24297   GO MNKD RSI 5 > 70 TREND1 06/24/17 11:45:21 AM
#24296   Denise the naysayers use the same tiresome arguments Hypi 06/24/17 10:18:43 AM
#24295   Looks like MOMENTUM to me..... Aloha96707 06/24/17 09:36:35 AM
#24293   Really? Think again! FIRST, look at script numbers WHS 06/24/17 06:09:09 AM
#24292   MNKD has yet to reach the levels of nobodysbusiness 06/24/17 04:23:19 AM
#24291 WHS 06/23/17 10:57:00 PM
#24290   Dream on. Read again. A company cannot lose TREND1 06/23/17 09:07:30 PM
#24289   Why not this for us: "A rights issue is scalpel 06/23/17 06:44:43 PM
#24288   The other possibility is that the price is nobodysbusiness 06/23/17 06:32:06 PM
#24287   risingskepticism TREND1 06/23/17 05:56:57 PM
#24286   MNKD went from RUSSELL 2000 TO RUSSELL MICRO TREND1 06/23/17 05:07:10 PM
#24285   5 million buys end of day and it no shorts 06/23/17 04:52:27 PM
#24284   no shorts Maybe the market figured out that TREND1 06/23/17 04:50:09 PM
#24283   Nothing criminal about short covering, lets just see tyfoidhana 06/23/17 04:36:56 PM
#24282   That was manipulation to allow almost 5 million no shorts 06/23/17 04:31:37 PM
#24281   no shorts MNKD closed down on the day. TREND1 06/23/17 04:27:10 PM
#24280   Wow. Now that is some manipulation to allow no shorts 06/23/17 04:19:39 PM
#24279   I never talk about my trades. TREND1 06/23/17 04:08:19 PM
#24278   TREND1--you do a lot of DD. How big conix 06/23/17 03:27:05 PM
#24277   Scripts climbing, revenue climbing, marketing/sales pushing hard, international no shorts 06/23/17 02:32:03 PM
#24276   Great news this morning on script counts. Slowly Denise Chanterelle 06/23/17 02:20:17 PM
#24275   Nice bid on $1.60 no shorts 06/23/17 01:02:52 PM
#24274   MannKind (NASDAQ:MNKD) investors have a something to smile TREND1 06/23/17 01:01:40 PM
#24273   VERY GOOD. I feel that MNKD should follow TREND1 06/23/17 12:50:30 PM
#24272   First of all a rights offering is far Hypi 06/23/17 12:21:30 PM